*The following content is generated by AI and is for reference only.
Bempedoic acid is a novel, first-in-class ATP citrate lyase (ACL) inhibitor developed for the management of hypercholesterolemia and mixed dyslipidemia. Chemically known as 2-[4-(4-chlorophenoxy)-5-oxo-1H-pyrrol-3-yl]acetic acid, this compound features the molecular formula C14H9ClN2O3 and carries the CAS registry number 1089667-36-8. Unlike traditional statins that inhibit HMG-CoA reductase in all tissues, bempedoic acid functions through a unique mechanism of action involving selective activation within the liver. It is administered as an inactive prodrug, bempedoic acid sodium salt, which requires conversion to its active form by the enzyme acyl-CoA synthetase short-chain family member 1 (ACSS1). This enzyme is highly expressed in the liver but absent in skeletal muscle, thereby minimizing the risk of myopathy and muscle-related adverse events often associated with statin therapy.
The primary clinical utility of bempedoic acid lies in its ability to significantly lower low-density lipoprotein cholesterol (LDL-C) levels when used as monotherapy or in combination with ezetimibe or statins. It is particularly indicated for patients who are statin-intolerant or those requiring additional LDL-C reduction despite maximally tolerated statin doses. By inhibiting ACL, it blocks the rate-limiting step in de novo cholesterol synthesis, leading to upregulation of LDL receptors on hepatocytes and increased clearance of circulating LDL particles from the bloodstream. Clinical trials have demonstrated its efficacy in reducing cardiovascular events in high-risk populations. Furthermore, because it does not accumulate in muscle tissue, it offers a favorable safety profile regarding muscle toxicity. Bempedoic acid represents a significant therapeutic advancement, providing a viable alternative for managing lipid disorders where conventional treatments fail or cause unacceptable side effects, ultimately contributing to improved cardiovascular health outcomes globally.